Mapi - Pharma (Mapi - Pharma) Days Payable : 0.00 (As of Jun. 2015)

View and export this data going back to . Start your Free Trial

What is Mapi - Pharma Days Payable?

Mapi - Pharma's average Accounts Payable for the six months ended in Jun. 2015 was $0.22 Mil. Mapi - Pharma's Cost of Goods Sold for the six months ended in Jun. 2015 was $0.00 Mil.

The historical rank and industry rank for Mapi - Pharma's Days Payable or its related term are showing as below:

MAPI's Days Payable is not ranked ^*
in the Drug Manufacturers industry.
Industry Median: 89.345
* Ranked among companies with meaningful Days Payable only.

Mapi - Pharma's Days Payable stayed the same from Jun. 2014 (0.00) to Jun. 2015 (0.00).

Mapi - Pharma Days Payable Historical Data

The historical data trend for Mapi - Pharma's Days Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mapi - Pharma Days Payable Chart

Mapi - Pharma Annual Data

Trend

Dec12

Dec13

Dec14

Days Payable

Mapi - Pharma Semi-Annual Data
	Dec12	Dec13	Jun14	Dec14	Jun15
Days Payable	-	-	-	-	-

Competitive Comparison of Mapi - Pharma's Days Payable

For the Drug Manufacturers - Specialty & Generic subindustry, Mapi - Pharma's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Mapi - Pharma's Days Payable Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Mapi - Pharma's Days Payable distribution charts can be found below:

* The bar in red indicates where Mapi - Pharma's Days Payable falls into.

Mapi - Pharma Days Payable Calculation

Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.

Mapi - Pharma's Days Payable for the fiscal year that ended in Dec. 2014 is calculated as

	Days Payable (A: Dec. 2014 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (A: Dec. 2013 )	+	Accounts Payable (A: Dec. 2014 ))	/	count )	/	Cost of Goods Sold (A: Dec. 2014 )	*	Days in Period
=	( (0.524	+	0.223)	/	2 )	/	0	*	365
=	0.3735					/	0	*	365
=	N/A

Mapi - Pharma's Days Payable for the quarter that ended in Jun. 2015 is calculated as:

	Days Payable (Q: Jun. 2015 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (Q: Dec. 2014 )	+	Accounts Payable (Q: Jun. 2015 ))	/	count )	/	Cost of Goods Sold (Q: Jun. 2015 )	*	Days in Period
=	( (0.223	+	0)	/	1 )	/	0	*	365 / 2
=	0.223					/	0	*	365 / 2
=	N/A

Mapi - Pharma Days Payable Related Terms

Thank you for viewing the detailed overview of Mapi - Pharma's Days Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

Mapi - Pharma (Mapi - Pharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Mapi - Pharma Ltd (NAS:MAPI) » Definitions » Days Payable

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.mapi-pharma.com

Mapi - Pharma Ltd was incorporated under the laws of the State of Israel on January 29, 2008. It is a development stage pharmaceutical company, engaged in the development of high-barrier to entry and high-added value generic drugs that include complex active pharmaceutical ingredients or APIs, formulations and life cycle management or LCM products that target large markets. The Company is developing two LCM products for the treatment of multiple sclerosis and neuropathic pain. It is also developing a portfolio of approximately 13 complex APIs. Its LCM portfolio focuses on market product, consisting of Glatiramer Acetate Depot, a once-monthly injection for the treatment of MS, Pregabalin ER, extended release capsules for the treatment of neuropathic pain and epilepsy, and Risperidone LAI, a depot formulation of Risperdal Consta, expected to be developed under the abbreviated new drug application ANDA or 505(b)(2) shortened regulatory pathway. Its competitors in the generic pharmaceutical products and LCM markets includes Teva Pharmaceutical Industries Ltd.; Impax Laboratories, Inc.; Alkermes Plc.; Momenta Pharmaceuticals, Inc.; and Andrx Corporation; a private U.S. company. The Company's current patent portfolio contains approximately 20 patent applications for complex APIs, formulations, polymorphs, and routes of synthesis. Its operations are subject to many governmental regulations.